Biochemical and Kinetic Study for the partially purified Lecithin: Cholesterol acyltransferase from serum cardiovascular disease
Article Sidebar
Main Article Content
Abstract
The study includes partial purification of Lecithin: Cholesterol acyltransferase (LCAT) from the blood serum of a person suffering from atherosclerosis. Several techniques were applied including ammonium sulphate precipitation, dialysis, ion exchange chromatography and electrophoresis. It was found that LCAT has one isoenzyme and the highest activity was (1073.46 × 10-3) unit/ml and a molecular weight of 62 KDa. The study also deals with characterizing of LCAT. It was found that the optimum pH and temp. of the enzyme were 7 and 35ºC.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Calobresi L., Simonelli S., Gomaraschi M. and Franceschini G.2012. Genetic lecithin cholesterol acyltranferase deficiency and cardiovascular disease. Athero., 229:299-306.
[2] Carmo R., Castro-Ferreira I. and Oliveira J.P. 2018. Lecithin cholesterol acyltransferase deficincy : a review for clinical mephroloists, Port. J Nephrol Hypert., 31(4): 286-292.
[3] Clay, F.S. and Ira J.G., 2016. Textbook of endocrinology. 13th ed., Elsevier B.V., UK.354.
[4] Kunnen S. and Van Eck M. 2012. Lecithin cholesterol acyltransferase old friend or foe in Atherosclerosis. J Lipid Res., 53(9): 1783-1799.
[5] Caster-Ferreira I., Carmo A. and Silva S.E. 2017. Missense LCAT gene mutation associated with an a typical phenotype of familial LCAT deficincy in two portuguese brothers. J I M D Rep.,(4): 113-116.
[6] Muclean J., Wionk K., Drayna D., Fielding C. and Lawn R. 1986. Human Lecithin cholesterol acyltransferase gen: complete gene sequence and sites of expression. Nucl acid Res., 14(23): 9397-9406.
[7] Najafian B., Lusco M.A. and Finn L.S. 2017. AJKD atlas of CVD pathology: Lecithin cholesterol acyltransferase (LCAT) deficincy. Am J CVD Dis., 63(3), e5-e6.
[8] Ahmad SB., Miller M. and Hanish S., 2016. Sequential kidny-Liver transplantation from the same living donor for LCAT . Clin Trans plant., 30(10): 1370-1374.
[9] Walker B., Colledge N.R., Ralston S. and Penman I. 2018. Daridson's principles and practice of medicine. 22 nd ed., Churchill Livingstone, UK.240-245.
[10] Francone O.L. and Fielding C.J. 1991. Effect of site –directed mutagenesis at residues cystein-31 and cysteine -184 on Lecithin cholesterol acyltransferase activity. Proc Nat Acod Sci USA.,88: 1716-1720.
[11] Shamburek R.D. Bakker-Arkema R. and Shamburek A.M. 2016. Safety and tolerability of ACP-501, a recombinant human lecithin: Cholesterol acyltransferase in a phase 1 Single – dose escalation study. Circ Res., 118(1): 73-82.
[12] Staels B., Vantol A., Skretting G. and Auwex J. 1992. Lecithin cholesterol acyltransferase gene expression is regulated in tissue-selective manner by fibrates. J Lipid Res., 33: 727-735.
[13] Homma Y., Ozawa H. and Kobayashi T.1994. Effect of bezafibrate therapy on subfractions of plasma low density lipoprotein and high density lipoprotien and on activaties of Lecithin cholesterol acyltransferase and cholesterol ester acyltransferase protein in patients with Hyper lipoproteinemia . Atherosclerosis., 106: 191-201.
[14] Mishra M., Durrington P. and Mackness M. 2005. The effect of atorvastatin on serum lipoprotein in acromegaly. Clin Endocrinol., 62:650-655.
[15] Yvan - Charut L., Matsurra F. and Wang N. 2007. Inhibition of cholesterol ester acyltransferase protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Ar terioscler Thromb Vasc Biol., 27:1132-1138.
[16] Kassai A., Illyes L. and Mirdamadi H.Z. 2007. The effect of atorvastatin therapy on Lecithin cholesterol acyltransferase: cholesterol ester acyltransferase protein and the antioxidant paraoxonal. Clin BioChem., 40:1-5.
[17] Karathanasis S.K., Freeman L.A., Gordon S.M. and Remaley A. 2017. The changing face of LDL and the best way to measure it . Clin Chem., 63: 196-210.
[18] Cecilia V. and Marina C. 2017. Therapies Targeting HDL-C Levels and HDL function 3rd ed., Elsevier, B.V.UK.115.
[19] Agnes B., Fogo M.D. and Michael K. 2017. In diagnostic atlas of renal pathology, 3rd ed., Elsevier B.V.UK, p.110.
[20] Alice O., Chiara P., and Laura C.2016. High density lipoprotein Lecithin cholesterol acyltransferase and other osclerosis. En M., 9:1-7.
[21] Robyt F.J. and White J.B. 1987. Biochemical techniques theory and practice. Book/cole Pulishing Co., USA. 125-135,141, 235-236, 246,263, 269.
[22] Milko R., Belzecki G. Kasperowicz A. and Tadeusz Michalowski T. 2010. Isolation and purification of chitinolytic enzymes of rumen ciliates ediplodinium maggii . XV: 189-196.
[23] Roy S. and Kumar V. 2014. Apractical approach on SDS PAGE for seperation of prorein., Int J SR., 3: 955-960.
[24] Manabe M., Abe T., Nozawa M., Maki A., Hirata M.Z. and Itakura, H. 1987. New substrate for determination of serum lecithin: cholesterol acyltransferase . J of Lip Res., (28): 1206-1215.
[25] Czarnecka H. and Yokoyama S. 1993. Regulation of lecithin-cholesterol acyltransferase reaction by acyl acceptors and demonstration of its ''Idling'' reaction. The J of Biol Chem., 268(26): 19334-19340.
[26] Clowick S.P. and Kaplan N.O. 1969. Method in enzymology, vol(XV), ACADEMIC Press New York, 543-548.
[27] Miller K.R., Wang J., Sorci-Thomas M., Anderson R.A. and Parks J.S.1996. Glycosylation structure and enzyme activity of lecithine- cholesterol aceyltransferase from human plasma, HePG2 cells, and baculoviral and chinese hamster ovary cell expression systems. J of lipid Resh., 37:551-561.
[28] Doi y. and Nishida T. 1983 Microheteogeneity and physical properties of human lecithin-cholesterol acyl-transferase, J Biol Chem., 258: 5840-5846.
[29] Knipping G.1986. Isolation and properties of procine lecithin-cholesterol acyltransferase. Eur J Biochem., 154: 289-294.
[30] Murray R.K., Bender D.A., Botham K.M., Kennelly, P.J., Rodwell R.W. and Weil, P.A. 2018. Harber's illustrated biochemistry. 32th ed., The Mecgraw-Hill Companies.
[31] Neslon D.L. and Cox M. 2005. Lehninger principle of biochemistry, 4th ed. USA, pp. 92, 205.
[32] Birari R.B. and Bhutani K.K. 2007. pancreatic lipase inhibitors from natural sources: Unexplored potential. Dru Dis Tod. 12: 879-889.